BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock



Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Financial figures, Fiscal year: from 01.07. to 30.06.

| | 20 | 2023 | | 2022 | | 2021 | |
|--------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|--|
| Financial figures | | Liabilities and equity | | Liabilities and equity | | Liabilities and equity | |
| Current assets | 621,482,000 | | 605,556,000 | | 510,606,000 | | |
| Common stock capital | | 1,576,000 | | 392,000 | | 390,000 | |
| Fixed assets | 2,112,233,000 | | 1,765,472,000 | | 1,839,234,000 | | |
| Equity capital of a company | | 1,966,516,000 | | 1,701,011,000 | | 1,571,234,000 | |
| Cash and cash equivalents | 180,571,000 | | 172,567,000 | | 199,091,000 | | |
| Accrued liabilities | | 0 | | 0 | | 0 | |
| Other assets | - | | - | | - | | |
| Current liabilities | | 128,509,000 | | 176,018,000 | | 152,284,000 | |
| Prepayments and accrued income | - | | - | | - | | |
| Non-current liabilities | | 638,690,000 | | 493,999,000 | | 626,322,000 | |
| Different income | | - | | - | | - | |
| Other liabilities | | 10,919,000 | | 17,239,000 | | 49,862,000 | |
| Total assets | 2,733,715,000 | 2,733,715,000 | 2,371,028,000 | 2,371,028,000 | 2,349,840,000 | 2,349,840,000 | |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 3,050 | 3,000 | 2,600 |
| Equity ratio | 71.94% | 71.71% | 67.22% |
| Debt-equity ratio | 39.01% | 39.45% | 48.77% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|-------|
| Tax Expense Rate | 15.71% | 12.70% | 5.80% |

BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

| Income statement | | | |
|--|---------------|---------------|-------------|
| | 2023 | 2022 | 2021 |
| Turnover | 1,136,702,000 | 1,105,599,000 | 931,032,000 |
| Net income | 285,193,000 | 271,930,000 | 140,324,000 |
| EBIT | 326,122,644 | 296,611,796 | 158,674,864 |
| Operating income before taxes | 338,659,000 | 301,386,000 | 148,175,000 |
| Cash Flow | 254,393,000 | 325,272,000 | 352,164,000 |
| Net interest income | -11,258,000 | -16,867,000 | -22,077,000 |
| Research and development expenses | 92,493,000 | 87,140,000 | 70,603,000 |
| Income taxes | 53,217,000 | 38,287,000 | 8,590,000 |
| Result from investments in subsidaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 347,346 | 343,473 | 333,739 |

Board of Directors

| Members of Management Board | | |
|-----------------------------|--------------------------------|--|
| | | |
| Robert Baumgartner | Chairman of Board of Directors | |
| Alpna Seth | Member of Board of Directors | |
| Joseph Keegan | Member of Board of Directors | |
| Judith Klimovsky | Member of Board of Directors | |
| Randolph Steer | Member of Board of Directors | |
| Roeland Nusse | Member of Board of Directors | |
| Rupert Vessey | Member of Board of Directors | |
| John Higgins | Member of Board of Directors | |
| Julie Bushman | Member of Board of Directors | |
| Charles Kummeth | Chairman of Managing Board | |
| Brenda S. Everson | Member of Executive Committee | |
| Jim Hippel | Member of Executive Committee | |
| Kevin Smyth | Member of Executive Committee | |